Semax: the ACTH-derived nootropic and neuroprotectant — 2026 evidence-based guide

If you could increase BDNF expression in your prefrontal cortex and hippocampus within hours — not weeks — and do it without exercise, meditation, or any behavioral change — you would have one of the most powerful neuroplasticity tools available. That is the promise of Semax, and the Russian clinical record spanning three decades suggests it is not merely a promise. In stroke wards across Moscow, Semax is standard-of-care neuroprotection, administered within hours of ischemic events to limit neuronal death and accelerate recovery.

Derived from ACTH — the pituitary hormone that normally tells your adrenals to produce cortisol — Semax uses only the fragment responsible for cognitive and neurotrophic effects, cleanly separated from any adrenal stimulation. The result is a peptide that enhances neuroplasticity, protects neurons from ischemic damage, and improves attention and memory, without raising cortisol, without sedation, and without dependence. The Western medical establishment has largely ignored it. The question is whether that reflects a genuine evidentiary gap or simply a regulatory and commercial one.

What is Semax?

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analogue of ACTH(4-10) — amino acids 4 through 10 of the 39-amino-acid adrenocorticotropic hormone — with a C-terminal Pro-Gly-Pro tripeptide extension that prevents enzymatic degradation and extends biological half-life.

ACTH(4-10) was identified in the 1970s as the minimal sequence within ACTH responsible for cognitive and behavioral effects (attention, memory consolidation, arousal) without adrenocortical stimulation. The adrenal effects of ACTH require the N-terminal sequence (residues 1-18); residues 4-10 alone have zero effect on cortisol production. Semax exploits this specificity: pure CNS neurotrophic and cognitive effects, with no endocrine consequences.

Semax has been approved in Russia since 1996 and is used clinically for: acute ischemic stroke (neuroprotection), chronic cerebrovascular insufficiency, cognitive disorders, optic nerve atrophy, and as a general nootropic for cognitive enhancement in healthy individuals under stress.

How does Semax work? Mechanism of action

• BDNF upregulation — The most consistently demonstrated mechanism. Semax increases BDNF mRNA and protein expression in hippocampus and cortex within 30 minutes to hours of administration. BDNF is the primary neurotrophin supporting synaptic plasticity, learning, memory formation, and neuronal survival
• NGF (nerve growth factor) increase — Alongside BDNF, Semax upregulates NGF expression — supporting cholinergic neuron survival and function (the neuronal population most affected in Alzheimer's disease)
• TrkB receptor sensitization — Semax may enhance the sensitivity of TrkB (the BDNF receptor) to its ligand, amplifying the downstream effects of both endogenous and Semax-induced BDNF
• Anti-inflammatory neuroprotection — Reduces microglial activation, TNF-α, and IL-1β expression in ischemic brain tissue. This limits secondary neuronal death following stroke or injury
• Dopaminergic and serotonergic modulation — Semax increases dopamine and serotonin turnover in specific brain regions, contributing to attention enhancement and mood stabilization without receptor downregulation
• Enkephalin system interaction — Like Selank, Semax inhibits enkephalin-degrading enzymes, increasing endogenous opioid peptide levels that contribute to neuroprotection and mild anxiolysis
• No adrenal stimulation — Does not activate MC2R (melanocortin-2 receptor) on adrenal cortex. Zero effect on cortisol, aldosterone, or adrenal function. Purely CNS-targeting

What does the research say?

Stroke neuroprotection (primary clinical indication)

Semax is used as standard neuroprotective therapy alongside thrombolysis in Russian stroke units. Clinical studies (Gusev et al., 2007) demonstrated that Semax 1% (12 mg/day intranasally) administered within the first 12 hours of ischemic stroke significantly improved neurological outcomes at 5 and 30 days compared to standard care alone. The mechanism: BDNF-mediated neuronal survival in the ischemic penumbra and reduced inflammatory secondary damage.

Cognitive enhancement in healthy adults

Studies in healthy volunteers and students showed improved attention, working memory, and information processing speed with 0.1% Semax intranasal over 7-14 day courses. The effects were most pronounced under conditions of cognitive load or fatigue. EEG studies confirmed increased cortical activation patterns consistent with enhanced attention and reduced fatigue.

Optic nerve neuroprotection

A unique indication for Semax in Russia is optic nerve atrophy. Clinical data shows improved visual acuity and visual field preservation with intranasal Semax in patients with glaucomatous and ischemic optic neuropathy — presumably through BDNF/NGF-mediated retinal ganglion cell survival.

Potential benefits of Semax

• Rapid BDNF elevation — The most pharmacologically direct way to increase BDNF expression short of intense exercise. Relevant for neuroplasticity, learning, memory, and neuroprotection
• Cognitive enhancement — Improved attention, processing speed, and working memory. Particularly effective under cognitive load or fatigue conditions
• Neuroprotection — Clinically demonstrated in stroke settings. May protect against neuronal damage from ischemia, oxidative stress, and neuroinflammation
• No cortisol elevation — Despite being derived from ACTH, Semax has zero adrenal effects. No stress-hormone consequences
• No sedation or psychomotor impairment — Unlike many cognitive-affecting medications, Semax preserves full alertness and motor coordination
• Fast onset — Intranasal delivery produces measurable effects within 15-30 minutes. Suitable for acute cognitive demands
• No dependence — No tolerance, addiction, or withdrawal syndrome reported across 30 years of clinical use
• Mild mood improvement — Through dopaminergic/serotonergic modulation and enkephalin system effects

Dosing protocols from clinical use

Side effects and risks

• Nasal irritation — Mild local irritation is the most commonly reported adverse effect. Occasionally nasal dryness with extended use
• Headache (rare) — Some users report mild headache, particularly at higher doses or during initial use. Typically transient
• Hair shedding (controversial) — Some community reports describe temporary increased hair shedding with high-dose Semax use. The mechanism (if real) may involve NGF/BDNF effects on hair follicle cycling. Not confirmed in clinical literature
• Overstimulation at high doses — The 1% concentration (designed for stroke emergencies) can feel cognitively intense. The 0.1% nootropic formulation is generally smooth
• No cortisol effects — Confirmed across all clinical studies. Semax does not raise cortisol, ACTH, or affect adrenal function in any way
• No cardiovascular effects — Heart rate, blood pressure unaffected at therapeutic doses
• No dependence or withdrawal — 30 years of clinical use with no reports of addiction or discontinuation syndrome

Legal and regulatory status (as of April 2026)

• Russia & CIS countries: Fully approved pharmaceutical product since 1996. Available by prescription in pharmacies. Standard-of-care for stroke neuroprotection
• United States: Not FDA-approved. Not on Category 2 restricted list. Available through some compounding pharmacies and research-chemical suppliers
• WADA: Not banned in competitive sport
• Compounding: Some US 503A pharmacies compound Semax with valid prescriptions
• N-Acetyl Semax (NASA) and Adamax variants: Modified versions with enhanced bioavailability exist in the research-chemical market but have NO clinical data

What has Huberman Lab said about Semax?

Andrew Huberman has discussed Semax in the context of BDNF elevation and neuroplasticity enhancement. He has highlighted it as one of the few pharmacological interventions that reliably and rapidly increases BDNF expression — positioning it alongside exercise, which is the gold-standard behavioral BDNF enhancer. The key distinction he has drawn: exercise increases BDNF globally and is free; Semax increases it rapidly and without physical effort but requires intranasal administration of a non-FDA-approved peptide.

Huberman has noted the significance of Semax being derived from ACTH without carrying adrenal effects — calling this "elegant pharmacological design" that separates the cognitive-enhancing properties of melanocortin signaling from the stress-hormone consequences. He has acknowledged the 30 years of Russian clinical use as more substantive than most peptide evidence bases, while noting the absence of FDA-style trials as a legitimate limitation for Western practitioners.

Who might consider Semax?

• Individuals seeking reliable, rapid BDNF enhancement for cognitive performance, neuroplasticity, or learning — particularly those already optimizing exercise and sleep
• People with cognitive fatigue, attention difficulties, or age-related cognitive decline not adequately addressed by lifestyle optimization
• Patients with optic nerve conditions or neuroprotection needs (under specialist guidance)
• Students or professionals facing intense cognitive demands who want nootropic support without stimulant side effects
• Those interested in neuroprotective strategies as part of a broader longevity-focused protocol

Who should exercise caution: individuals with manic tendencies or bipolar disorder (BDNF elevation could theoretically exacerbate mania in susceptible individuals), anyone unable to source verified-quality product, those expecting Semax to replace foundational cognitive health practices (sleep, exercise, nutrition), or people with brain tumors (neurotrophic factor elevation near malignant tissue is theoretically concerning).

Frequently asked questions

Bottom line

Semax may be the most pharmacologically sophisticated nootropic peptide currently available. It reliably increases BDNF expression — the single most important molecule for neuroplasticity and cognitive adaptation — without raising cortisol, without sedation, without dependence, and with 30 years of clinical use supporting its safety profile. The stroke neuroprotection data gives it a clinical seriousness that most nootropics lack.

The caveats are the same as for Selank: Russian regulatory standards differ from FDA requirements; most published data is in Russian journals; independent Western trials are absent; and quality assurance for non-Russian users depends on sourcing. But unlike most peptides in this series, Semax has a track record of actual clinical use — not just animal models and forum posts.

For someone who has already optimized sleep, exercise, and metabolic health and wants a pharmacological tool for additional cognitive support, Semax represents one of the better-grounded options. It is not a substitute for the behavioral foundations (exercise remains the most powerful BDNF enhancer available), but as an adjunct, the biological rationale and clinical track record are stronger than most alternatives.

Keep reading

Peptides

Selank: the Russian anxiolytic nootropic peptide — 2026 evidence-based guide

Peptides

Dihexa: the "million-fold BDNF" cognitive peptide — 2026 evidence-based guide

Peptides

Bromontan: the Soviet adaptogenic stimulant — 2026 evidence-based guide